The basics:
- Bayer remains among the few major drugmakers without a White House MFN agreement
- Company executives are evaluating potential drug pricing, tariff implications
- White House says MFN agreements now cover 89% of the branded drug market
More than two dozen drugmakers have reached deals with the White House to lower prescription drug costs in exchange from an exemption from U.S. pharmaceutical tariffs. However, Bayer is not one of them.
During the Whippany-based pharma giant’s Nov. 3 third quarter earnings call, Bayer Chief Financial Officer Judith Hartmann said executives continue to evaluate what the Trump administration’s Most Favored Nation policies could mean for its pricing and launch strategies. Hartmann added that Bayer already factored U.S. tariffs on patented pharmaceuticals into guidance for this year.
Bayer CEO Bill Anderson said, “With respect to MFN, we’re working on that right now in the U.S., and that’s an active topic for us, but we expect to have a good resolution that’s good for America, good for Bayer.”
The White House called on the industry in July 2025 to reduce costs voluntarily. Since then, it has announced deals with 26 pharmaceutical manufacturers. Companies entering agreements include New Jersey-based firms Bristol Myers Squibb, Teva Pharmaceuticals, Novo, Johnson & Johnson, Merck, Novartis and Sanofi.
The administration recently reported that 89% of the branded drug market now has MFN agreements. The White House added it expects estimated total savings from the MFN arrangements to reach $600 billion over the next decade.
Made in the USA
Amid pressure from the administration, pharma companies have also unveiled billions of dollars to boost domestic manufacturing capabilities.
Drugmakers participating in the MFN initiative have been offered incentives, such as a three-year reprieve from the Section 232 tariff on pharmaceutical imports.
While tariffs could cost the pharmaceutical industry tens of billions of dollars annually, individual drugmakers could face costs in the hundreds of millions, depending on their reliance on imported products and ingredients, according to an estimate from the Tax Foundation.
As one of “the few companies” without an MFN deal, Bayer is “exposed to potential tariff impact,” said Stefan Oelrich, the company’s pharmaceuticals division president. It also faces possible effects from trial programs developed by the Centers for Medicare and Medicaid Services to embed MFN drug pricing into government healthcare programs, he said.
“This is something that we’re currently discussing still,” he said, adding that the company will provide an update when it reports its Q1 results in May 2027.
Building in the Buckeye State
Oelrich also emphasized Bayer’s commitment to boosting its U.S. footprint.
Last month, the company unveiled plans to build a $2.2 billion pharmaceutical manufacturing campus in Ohio. According to Bayer, the state-of-the-art facility is designed to support its growing portfolio in oncology, cardiovascular and renal care.

It will also complement Bayer’s U.S. headquarters in Whippany, as well as research, development and manufacturing operations in locations including Pittsburgh, Berkeley, Cambridge, Research Triangle Park and San Diego, the company said.
The new investment builds on more than $7 billion Bayer says it has spent on domestic research, development and manufacturing over the past five years.
“The Ohio investment clearly is a sign of our strategy of renewed focus on the U.S. market really coming through,” Oelrich said. “That includes bringing manufacturing to where our biggest markets are in the world that we live in now.”
Looking ahead
Even after Democrats regained control of Congress in this week’s midterm elections, some pharma leaders said they expect little change to their MFN deals.
BioSpace reported that Novo CEO Mike Doustdar said, “There’s always been a strong bipartisan support from both sides of the aisle for what we do. We improve health at scale — whether you’re Republican or Democrat, you welcome that for your constituents.”
He also pledged to work closely with either party on “making sure that we can be a meaningful partner” to the U.S.
What’s in a name?
In September, Novo Nordisk announced it will now be known to consumers as Novo. Learn the reason behind the change here.
The Danish drugmaker has its U.S. headquarters in Plainsboro. Its portfolio includes blockbuster GLP-1 drugs Wegovy and Ozempic.
Pfizer CEO Albert Bourla also downplayed the likelihood of legislative changes. He believes a divided government would make it difficult to advance new policies.
“In 2025, I was really scared about the implications that either tariffs or MFN could have,” he said during the company’s Nov. 3 Q3 call. “Through the successful navigation of those issues, we brought the stability that is now projected to last and has brought, I think, this confidence back to the investor to invest in the in the industry in our sector.”
Down to the details
Still, drug pricing could become an issue again, BioSpace reported.
Citing an analysis by Leerink Partners, the trade publication reported that Democrats may take a closer look at the administration’s MFN negotiations. Details of those deals have been kept under wraps by the administration and drugmakers.
The firm also said President Donald Trump could push drugmakers for a better deal when the current agreements expire in December 2028, according to BioSpace.
The post Bayer weighs drug pricing deal with Trump admin as tariff risks loom appeared first on NJBIZ.

